mcla-117
mAbexperimentalMulti-specific
Clinical trial activity
1 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2016 (NCT03038230)
Timeline
2010s
- Jan 1, 2016
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
CD3E activator
CLEC12A inhibitor
Chemistry & pharmacology
- Multi-specific
- Yes
Oral
No
Parenteral
No
Topical
No
Also known as
- mcla-117
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03038230 | Phase 1 | Apr 1, 2016 | B&C Group (Belgium), Eurofins, Free University of Amsterdam, Kinesis Pharma, LGC Limited, Merus Labs, Pharmaceutical Research Associates, Inc. (PRA) |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| B&C Group (Belgium) | For profit | 1 | 0 | 1 | 2016 |
| Eurofins | For profit | 1 | 0 | 1 | 2016 |
| Free University of Amsterdam | Academic/Hospital | 1 | 0 | 1 | 2016 |
| Kinesis Pharma | For profit | 1 | 0 | 1 | 2016 |
| LGC Limited | For profit | 1 | 0 | 1 | 2016 |
| Merus Labs | For profit | 1 | 1 | 1 | 2016 |
| Pharmaceutical Research Associates, Inc. (PRA) | For profit | 1 | 0 | 1 | 2016 |
7 organizations
Page 1 / 1